Anti CD44 Antigen v9 mAb (Clone RV3)

Cosmo Bio LTD

Catalog No: CAC-LKG-M003

• 
• 
• 
• 
• 

Catalog numbers beginning with "CAC" are antibodies from our exclusive Cosmo Bio Antibody Collection. Visit the CAC Antibody homepage to browse the collection list, organized by research topic.

Please visit our CD44 Variant Antibody homepage to see related products and view an annotated bibliography of citations.

Click here to browse a well organized list of products for Bone, Collagen, and Extracellular Matrix research.

Click here for more information and to see all exosome related products from Cosmo Bio USA.

Application: FC, IP, ELISA, IF, IHC(p), WB, ICC 
Clonality: Monoclonal 
Host: Rat 
Purification: Ig-PG 
Reactivity: Human 

CD44 is a single-pass type I transmembrane protein and functions as a cellular adhesion molecule for hyaluronic acid, a major component of the extracellular matrix. It exists in numerous isoforms that are generated through alternative splicing of CD44 precursor mRNA. Whereas the standard isoform of CD44 (CD44s) is expressed predominantly in hematopoietic cells and normal epithelial cell subsets, CD44v (variant) isoforms, which contain additional insertions in the membrane-proximal extracellular region, are highly expressed in epithelial-type carcinomas. Moreover, CD44 is reported to be a cell surface marker for cancer stem cells (CSCs) derived from solid tumors including breast, prostate, colon, head and neck and pancreatic cancer. Expression of CD44, especially variant isoforms (CD44 v8-10), contributes to reactive oxygen species (ROS) defense through upregulation of the synthesis of reduced glutathione (GSH), the primary intracellular antioxidant. CD44 v8-10 interacts with and stabilizes xCT, a subunit of the cystine-glutamate transporter xc(-), and thereby promotes cystine uptake for GSH synthesis. The ability to avoid the consequences of exposure to high levels of ROS is required for cancer cell survival and propagation in vivo. CSCs (whose defense against ROS is enhanced by CD44v8-10) are thus thought to drive tumor growth, chemoresistance and metastasis. Clone RV3 (a monoclonal antibody specific for human CD44 v9) can be used in flow cytometry, and importantly, for the enrichment of CSCs using FACS. RV3 can be applied towards understanding a variety of molecular mechanisms and towards the development of new medicines against cancer stem cells using in vitro cell-based assays such as the "in vitro sphere formation" and "in vivo lung metastasis" assays.

References:
1) Nagano O., et al., Oncogene. 2013 Jan 21., 1-8. PMID:23334333
2) Ishimoto T., et al., Cancer Cell. 2011 Mar 8;19(3):387-400. PMID : 21397861
3) Yae T., et al., Nat Commun. 2012 Jun 6;3:883. PMID: 22673910
4) Tsugawa H., et al., Cell Host Microbe. 2012 Dec 13;12(6):764-77. PMID: 23245321
5) Tanabe KK., et al., Lancet. 1993 Mar 20;341(8847):725-6. PMID: 8095628

Citations for Anti CD44 Antigen v9 mAb (Clone RV3) – 7 Found

Akamine et al. 2019. The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation. Ann Surg Oncol. 26(5):1544-51.   , Journal

Ogihara et al. 2019. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer Sci. 110(4):1431-1441.   , Journal

Takeda et al. 2019. Disruption of Endolysosomal RAB5/7 Efficiently Eliminates Colorectal Cancer Stem Cells. Cancer Res. 79(7):1426-37.   , Journal

Osaki et al. 2019. Interferon-γ directly induces gastric epithelial cell death and is required for progression to metaplasia. J Pathol. 247(4):513-23.   , Journal

Tokunaga et al. 2019. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast Cancer. 26(1):47-57.   , Journal

Jeong et al. 2016. Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. United European Gastroenterology Journal. 5(1):.   , Journal

Nagano et al. 2013. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 32(44):5191-8.   , Journal
- Comments: This review paper describes the discovery of a critical association between a variant form of CD44 (CD44v8-10; recognized by clone RV3 available from Cosmo Bio) and xCT, a subunit of the cystine-glutamate antiporter required for generation of intracellular antioxidant GSH. CD44v8-10 is thought to be a cancer stem cell marker that acts in part by promoting resistance to ROS, thereby accounting for their enhanced resistance to chemo and radiotherapy.